Avantium appoints Gunnar Staaf
pharmafile | January 19, 2010 | Appointment | Sales and Marketing | appointment, sales and marketing
Amsterdam-based technology company Avantium has appointed Gunnar Staaf as chief executive of its pharma business in preparation for spinning it out.
Staaf previously worked in a range of commercial and executive positions at Astellas Pharma, Novartis and Lilly, as well as Cambridge, UK biotech company Serentis.
Avantium plans to create a stand-alone pharmaceutical company based on an offering that combines proprietary crystallisation services to pharma and biotech companies sector and services to develop improved forms of existing drugs.
Avantium chief executive Tom van Aken said: “With his background in the pharmaceutical industry and wealth of commercial experience, Gunnar is a tremendous addition to our company.
“The appointment of Gunnar is an important step towards a focused pharmaceutical company.”
After the spin-out of its pharmaceutical business, Avantium will focus on its cleantech and chemicals activities, including its Furanics bioplastics and biofuels programme, and its high-throughput catalysis services and systems offering.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …